Pluvicto

Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data
Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data
BioSpace
ESMO
Novartis
prostate cancer
Pluvicto
radiopharmaceuticals
Flag link:
Novartis plant cleared to produce in-demand cancer drug
Novartis plant cleared to produce in-demand cancer drug
BioPharma Dive
Novartis
drug manufacturing
Pluvicto
New Jersey
cancer
radiopharmaceuticals
Flag link:
Novartis takes step toward expanding supply of in-demand cancer drug
Novartis takes step toward expanding supply of in-demand cancer drug
Biopharma Dive
Novartis
Pluvicto
prostate cancer
Flag link:
A year of two halves for US approvals
A year of two halves for US approvals
EP Vantage
FDA
drug approvals
Mounjaro
Eli Lilly
Vabysmo
Roche
Opdualag
Bristol Myers Squibb
Carvykti
JNJ
Vtama
Roivant
Pluvicto
Novartis
Flag link:
In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise
In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise
BioSpace
Novartis
prostate cancer
Pluvicto
clinical trials
patents
patent cliff
Flag link:
Lantheus has three shots on goal to challenge Novartis
Lantheus has three shots on goal to challenge Novartis
EP Vantage
Lantheus Medical
Novartis
Point Biopharma
Pluvicto
Luthathera
Flag link:
Novartis' surprise radiotherapy production halt nearing an end as FDA docs shed light on plant woes
Novartis' surprise radiotherapy production halt nearing an end as FDA docs shed light on plant woes
Fierce Pharma
Novartis
radiotherapy
FDA
Lutathera
Pluvicto
Flag link:
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?
Motley Fool
Novartis
M&A
AveXis
Zolgensma
Endocyte
Pluvicto
The Medicines Company
Levqio
Flag link: